Divi's Laboratories Limited

As of June 30, 2026, Divi's Laboratories Limited carries a market capitalization of 1.75T, placing it among publicly traded companies globally. Its enterprise value stands at 1.75T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Divi's Laboratories Limited's next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Divi's Laboratories Limited has 265.47M shares outstanding.

As of June 30, 2026, Divi's Laboratories Limited trades at a trailing price-to-earnings ratio of 63.04.

As of June 30, 2026, Divi's Laboratories Limited trades at an EV/EBITDA multiple of 46.94 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 16.04 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 53.91 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.75T versus a market cap of 1.75T, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.81M in revenue per employee across its workforce of 18,798.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Divi's Laboratories Limited recorded 8.75B in income tax expense. That works out to an effective tax rate of 23.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 36.56B, leaving 27.81B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Divi's Laboratories Limited's stock has gained approximately 38.30% over the past 52 weeks. The 50-day moving average sits at 9,141.33, while the 200-day moving average is 7,219.13.

Over the twelve months ended June 30, 2026, Divi's Laboratories Limited generated 109.25B in revenue and converted that into 27.81B in net income, yielding earnings per share of 104.73. EBITDA reached 37.34B, while operating income came in at 33.25B.

Over the twelve months ended June 30, 2026, Divi's Laboratories Limited posted a gross margin of 63.33, reflecting its pricing power and cost economics. The operating margin of 30.43 and net profit margin of 25.46 provide insight into operational efficiency.

Divi's Laboratories Limited's most recent stock split took place on September 23, 2015 with a 1:2 split ratio.